Evidence map›Paper›PMID 37222282›Full record

ReviewBiochemical Society transactions2023

The Nrd1-Nab3-Sen1 transcription termination complex from a structural perspective.

Belén Chaves-Arquero, José Manuel Pérez-Cañadillas

Open access · hybridAbstract readReview
In one paragraph

Review in Biochemical Society transactions, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Belén Chaves-Arquero *Department of Structural and Chemical Biology, Center for Biological Research 'Margarita Salas', CIB, CSIC, Av. Ramiro de Maeztu 9, 28040 Madrid, Spain.ORCID 0000-0002-2761-2336
José Manuel Pérez-Cañadillas *Department of Biological Physical Chemistry, Institute of Physical-Chemistry 'Blas Cabrera', CSIC, C/Serrano 119, 28006 Madrid, Spain.ORCID 0000-0002-8266-5502
Centro de Investigaciones Biológicas Margarita Salas · ESConsejo Superior de Investigaciones Científicas · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A substantial part of living cells activity involves transcription regulation. The RNA polymerases responsible for this job need to know 'where/when' to start and stop in the genome, answers that may change throughout life and upon external stimuli. In Saccharomyces cerevisiae, RNA Pol II transcription termination can follow two different routes: the poly(A)-dependent one used for most of the mRNAs and the Nrd1/Nab3/Sen1 (NNS) pathway for non-coding RNAs (ncRNA). The NNS targets include snoRNAs and cryptic unstable transcripts (CUTs) generated by pervasive transcription. This review recapitulates the state of the art in structural biology and biophysics of the Nrd1, Nab3 and Sen1 components of the NNS complex, with special attention to their domain structures and interactions with peptide and RNA motifs, and their heterodimerization. This structural information is put into the context of the NNS termination mechanism together with possible prospects for evolution in the field.

Indexed as

Saccharomyces cerevisiae ProteinsDNA HelicasesGene Expression Regulation, FungalNuclear ProteinsRNA-Binding ProteinsRNA HelicasesRNA Polymerase IISaccharomyces cerevisiaeDNA HelicasesNuclear ProteinsRNA-Binding ProteinsRNA HelicasesRNA Polymerase IISaccharomyces cerevisiae ProteinsCUTsNab3Nrd1pervasive transcriptionprotein structureSen1

Identifiers

PMID37222282
PMCPMC10317158
OpenAlexW4377940128

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.